Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired H
Go back to Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired H| (NASDAQ: RYTM) | Delayed: 99.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $99.27 | 52 Week High | $ | |||
| Open | $99.27 | 52 Week Low | $ | |||
| Day High | $99.27 | P/E | N/A | |||
| Day Low | $99.27 | EPS | $ | |||
| Volume | 135 | |||||
